❤️ Cardiovascular Innovation & ACC25 Highlights | Smart Wearables, Gene Therapy, AI in Heart Failure
Let’s take a look at the latest cardiovascular breakthroughs from this week’s update, including key takeaways from ACC25, advancements in heart failure diagnostics, AI applications, remote monitoring, and gene therapy innovations pushing the future of heart health forward. From semaglutide’s risk reduction in diabetes to smart textiles and cardiac MRI, this episode dives deep into the technologies and trials that are reshaping how we detect, manage, and treat cardiovascular disease.
🔍 What’s Inside This Week’s Cardiovascular Update:
✔️ ACC25 insights on AI, heart failure, and “living ecosystems” for regulatory innovation
✔️ Hearing loss linked to 28% higher risk of heart failure
✔️ Smart shirt predicts early cardiac risk via heart rate recovery
✔️ 4F-PCC reduces interventions and bleeding in cardiac surgery
✔️ FFR-guided PCI matches CABG at 5 years (FAME 3 trial)
✔️ Oral semaglutide cuts MACE risk by 14% (SOUL trial)
✔️ Cardiac MRI refines risk stratification in CTD-PAH
✔️ Rural–urban disparities in cardiometabolic disease burden
✔️ Verve-102 gene therapy achieves up to 69% LDL reduction with no serious AEs
✔️ Lepodisiran targets lipoprotein(a) in high-risk patients
✔️ Emory’s Phase III cell therapy trial in ischemic heart failure now underway
📢 Stay Ahead in Cardiovascular Research!
✅ Like, share, and subscribe for weekly insights on heart disease, gene therapy, diagnostics, and digital health
#CardiovascularHealth #ACC25 #HeartFailure #GeneTherapy #SmartWearables #LDLCholesterol #DiabetesCare #CardiologyResearch #DigitalHealth #HealthEquity #AIinMedicine #CardiacMRI #LucidQuest #ClinicalTrials #HeartDisease #HealthcareInnovation